Clinical stage biotechnology company within the therapeutic field of life-threatening fungal diseases Biosergen AB (STO:BIOSGN) announced on Friday that it has successfully completed the treatment of the first patient with BSG005, a promising candidate for addressing invasive fungal infections, which claim 2.5 million lives annually.
The first patient, a 47-year-old male with uncontrolled diabetes and Mucormycosis, showed significant improvement, avoiding the need for lung removal surgery and experiencing no major safety issues. BSG005, designed to be safe, effective, and broad-spectrum, is a critical development amid rising resistance to current therapies.
Five trial sites in India are now fully operational, with recruitment efforts ongoing despite challenges posed by stringent eligibility criteria. Alkem Laboratories Ltd, a top Indian pharmaceutical company, actively supports the trial and will finance future phases in India. The trial is expected to complete by January 2025, with the goal of improving survival rates in patients with resistant fungal infections. Biosergen plans to provide ongoing updates on patient outcomes.
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics
Merck's GARDASIL 9 shows promise in preventing HPV infection in Japanese males
Pheon Therapeutics names new independent, non-executive director
Solu Therapeutics names new chief medical officer
Tyra Biosciences names new chief medical officer
Arecor reports positive Phase I Results for AT278 insulin at EASD 2024